Integrated DNA Technologies (IDT) is a leader in the manufacture and development of products for the research and diagnostic life science market. The largest supplier of custom nucleic acids in the world, IDT serves academic research, biotechnology, and pharmaceutical development.
IDT products support a wide variety of applications.
Founded in 1998, Yole Développement, the "More than Moore" market research & strategy consulting company has grown to become a group of companies providing marketing, technology and strategy consulting, media in addition to corporate finance services Yole Développement group provides market research, technology analysis, strategy consulting, targeted media, and financial advisory services. We have a global vision and customer base...
The “More than Moore” company Yole and its partners System Plus Consulting, Blumorpho, PISEO and KnowMade support industrial companies, investors and R&D organizations worldwide to help them understand markets and follow technology trends to develop their business...
Synthego is a leading provider of genome engineering solutions. The company’s flagship product, CRISPRevolution, is a portfolio of synthetic RNA designed for CRISPR genome editing and research. Synthego’s vision is to bring precision and automation to genome engineering, enabling rapid and cost-effective research with consistent results for every scientist.
Headquartered in Silicon Valley, California, Synthego customers include leading institutions in 31 countries around the world, and 9 of the top 10 global biology universities.
FluidFM® technology optimises CRISPR-Cas delivery and the transfection of plasmids. Perform fast injection of CRISPR-Cas complexes, even in cells difficult to target with conventional CRISPR delivery methods.
Using the FluidFM BOT system to deliver your CRISPR-Cas complex, you can selectively choose the cell you want to inject within a cell culture. Deliver your CRISPR-Cas complex directly to where it is required: the nucleus. This is performed without affecting the neighbouring cells.
Transfection of plasmids with FluidFM nanoinjection enables the delivery of genetic material even into difficult to transfect cells. In contrast to conventional transfection methods, no toxic compounds are necessary to allow the DNA vector to enter the cell. Observe the expression of your plasmid as early as 3h post injection.
The FluidFM BOT system is an unmatched tool to introduce a vast variety of materials of your choice into a cell. From small molecules to proteins, RNAs, and plasmids, the FluidFM nanosyringe can be loaded with – and thus deliver – virtually any kind of liquid-based solution in a cell-context preserving, non-destructive and measurable manner.
The efficiency of the FluidFM nanoinjection has already been demonstrated in various kind of cell types such as HeLa, HEK, CHO or human iPS cells.
FluidFM nanoinjection combined with other FluidFM applications, such as extraction and manipulation, makes the FluidFM BOT an incredible tool for biologists. The system has been designed specifically to address bottlenecks in the pipelines of pharmaceutical drug development and genetic editing at the single cell level.
FluidFM technology unites the best features of microfluidics and force microscopy by introducing a microscopic channel into force sensitive probes. The result is the FluidFM probe, such as the FluidFM nanosyringe, the heart of our patented FluidFM technology.
Cytosurge AG successfully develops, manufactures and distributes cutting-edge and unique high-precision nanotechnology instruments as well as robotic systems based on its patented FluidFM® technology. Whether via the FluidFM ADD-ON, a powerful upgrade solution for your AFM, the FluidFM BOT, a fully integrated system for cell research, or via the award-winning FluidFM µ3Dprinter for 3D metal printing at the micrometre scale, Cytosurge provides leading-edge tools and processes to those who need or want to go beyond current technological boundaries.
As a global leader in R&D genomics services, GENEWIZ leads the way in providing superior data quality with unparalleled technical support to enable researchers around the world to advance their scientific discoveries faster than ever before.
GENEWIZ offers a range of CRISPR/Cas9 solutions, including gRNA construct synthesis, synthetic DNA libraries, Sanger validation of constructs, PCR + sequencing analysis, and next-generation sequencing to confirm on-target/off-target effects.
The leading global provider of thought leadership and insight dedicated to the pharma/healthcare industry the pharmaphorum channels bring together news, analysis and expert perspectives from all stakeholders in health, including commercial providers, healthcare professionals and patients.
This thought-provoking content keeps the pharmaceutical industry informed and connected, driving collaboration and innovation. Our unique output is accessed via https://pharmaphorum.com/rd/ and also our quarterly journal Deep Dive http://bit.ly/DDdigital.
BlueSEQ Partners is a specialized global consulting firm focused on the Life Sciences, Digital Biology, and Genomics markets. Their unique blend of Business Management, Technology Understanding, and Strategy and Execution capabilities is what separates them from other consulting firms.
The BlueSEQ Partners group offers customized consulting teams to help their clients gain access to relevant industry C-level expertise, which many of their consultants have achieved over many years’ worth of successful management and scientific operations.
Methods and Protocols (ISSN 2409-9279; www.mdpi.com/journals/mps) is an open access journal devoted to the publication of new procedural approaches and cutting-edge methodological developments. The ultimate objective of this new forum of scientific communication is to provide researchers with an indispensable tool, enabling better use of the latest scientific technologies. With a broad and totally interdisciplinary focus, Methods and Protocols was established with the objective of facilitating cross-fertilization and cross-talk in the scientific arena. Methods and protocols in Life Sciences, Chemistry, Biomedical Sciences, Engineering, and in their intersections such as Biotechnology and Nanotechnology constitute the core of the journal.
You are welcome to submit your manuscripts to our Topical Collection on “Gene Editing” (http://www.mdpi.com/journal/mps/special_issues/Gene-Editing). This Topical Collection aims to provide a forum for discussions on the latest technical developments in the fields of general genome engineering technologies, including (i) the establishment of cell culture systems, and (ii) the development of established and emerging organismal models by CRISPR/Cas9 or similar genome engineering tools. Our topical collection aims to keep up with the most recent developments, refinements, and latest achievements in gene editing available today. We encourage contributions from laboratories working at the forefront of the development of novel CRISPR/Cas9 approaches, with the goal of sharing these details and accelerating the speed of functional genetic discovery across the tree of life, in well-established as well as in emerging model systems.
Interested in partnering with Precision CRISPR Congress? Take a look at the Partnership Prospectus.
Hanson Wade's goal is to accelerate progress within organisations and across industries. Our primary method for achieving this is by creating exclusive business conferences that gather together the world's smartest thinkers and doers.